Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;4(2):91-8.
doi: 10.1556/EuJMI.4.2014.2.1. Epub 2014 May 21.

Production of recombinant antibodies using bacteriophages

A M Shukra  1 , N V Sridevi  1 , Dev Chandran  1 , Kapil Maithal  1
Affiliations
Review

Production of recombinant antibodies using bacteriophages

A M Shukra et al. Eur J Microbiol Immunol (Bp). 2014 Jun.

Abstract

Recombinant antibody fragments such as Fab, scFv, diabodies, triabodies, single domain antibodies and minibodies have recently emerged as potential alternatives to monoclonal antibodies, which can be engineered using phage display technology. These antibodies match the strengths of conventionally produced monoclonal antibodies and offer advantages for the development of immunodiagnostic kits and assays. These fragments not only retain the specificity of the whole monoclonal antibodies but also easy to express and produce in prokaryotic expression system. Further, these antibody fragments are genetically stable, less expensive, easy to modify in response to viral mutations and safer than monoclonal antibodies for use in diagnostic and therapeutic applications. This review describes the potential of antibody fragments generated using phage display and their use as diagnostic reagents.

Keywords: antibody fragments; bacteriophage; diagnostics; phage display; therapeutics.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Spleen cells from mice (or) peripheral blood lymphocytes from humans
See this image and copyright information in PMC

References

    1. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994 Aug;38(8):1695–1702. - PMC - PubMed
    1. Casadevall A. Passive antibody therapies: progress and continuing challenges. Clin Immunol. 1999 Oct;93(1):5–15. - PubMed
    1. Levy SB. Balancing the drug-resistance equation. Trends Microbiol. 1994 Oct;2(10):341–342. - PubMed
    1. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. N Engl J Med. 2009 Jan 29;360(5):439–443. - PubMed
    1. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000 Oct;13(4):602–614. - PMC - PubMed